ARX Stock Overview
Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and sells medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ARX from our risk checks.
Aroa Biosurgery Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.50 |
| 52 Week High | AU$1.09 |
| 52 Week Low | AU$0.47 |
| Beta | 0.68 |
| 1 Month Change | -8.26% |
| 3 Month Change | -31.51% |
| 1 Year Change | -52.61% |
| 3 Year Change | -56.52% |
| 5 Year Change | n/a |
| Change since IPO | -62.96% |
Recent News & Updates
Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation
Mar 25
Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge
Jan 30Recent updates
Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation
Mar 25Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge
Jan 30Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors
Nov 14Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts
Nov 02Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price
Oct 25We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth
May 13Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results
May 26An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued
Mar 22Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?
Feb 24Don't Ignore The Fact That This Insider Just Sold Some Shares In Aroa Biosurgery Limited (ASX:ARX)
Feb 24Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 44% Above Its Share Price
Dec 16
Shareholder Returns
| ARX | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -2.0% | 2.8% | 0.9% |
| 1Y | -52.6% | -8.0% | 5.7% |
Price Volatility
| ARX volatility | |
|---|---|
| ARX Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: ARX's share price has been volatile over the past 3 months.
Volatility Over Time: ARX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Brian Ward | aroabio.com |
Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and sells medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobia Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; and Reinforced Bioscaffolds, a surgical product for use in ventral hernia repair and abdominal wall reconstruction. The company was incorporated in 2007 and is headquartered in Auckland, New Zealand.
Aroa Biosurgery Limited Fundamentals Summary
| ARX fundamental statistics | |
|---|---|
| Market cap | AU$172.10m |
| Earnings (TTM) | -AU$7.57m |
| Revenue (TTM) | AU$60.17m |
2.9x
P/S Ratio-22.7x
P/E RatioIs ARX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARX income statement (TTM) | |
|---|---|
| Revenue | NZ$65.89m |
| Cost of Revenue | NZ$10.23m |
| Gross Profit | NZ$55.66m |
| Other Expenses | NZ$63.95m |
| Earnings | -NZ$8.29m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 29, 2024
| Earnings per share (EPS) | -0.024 |
| Gross Margin | 84.47% |
| Net Profit Margin | -12.58% |
| Debt/Equity Ratio | 0% |
How did ARX perform over the long term?
See historical performance and comparison